Register entry
Actelion Pharmaceuticals US, Inc.
- Registered sites
- 0
- Drug products
- 21
- Live patents
- 149
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
149Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| OPSUMIT | MACITENTAN | Sept 2026 |
| OPSUMIT | MACITENTAN | Mar 2027 |
| OPSUMIT | MACITENTAN | May 2027 |
| OPSUMIT | MACITENTAN | Nov 2027 |
| OPSUMIT | MACITENTAN | Oct 2028 |
| OPSUMIT | MACITENTAN | Apr 2029 |
| OPSUMIT | MACITENTAN | Apr 2029 |
| OPSUMIT | MACITENTAN | Oct 2029 |
| OPSYNVI | MACITENTAN; TADALAFIL | Sept 2026 |
| OPSYNVI | MACITENTAN; TADALAFIL | Mar 2027 |
| OPSYNVI | MACITENTAN; TADALAFIL | Apr 2029 |
| OPSYNVI | MACITENTAN; TADALAFIL | Oct 2029 |
| TRACLEER | BOSENTAN | Dec 2027 |
| UPTRAVI | SELEXIPAG | Oct 2026 |
| UPTRAVI | SELEXIPAG | Apr 2027 |
| UPTRAVI | SELEXIPAG | Aug 2029 |
| UPTRAVI | SELEXIPAG | Feb 2030 |
| UPTRAVI | SELEXIPAG | Jun 2030 |
| UPTRAVI | SELEXIPAG | Aug 2030 |
| UPTRAVI | SELEXIPAG | Dec 2030 |
| UPTRAVI | SELEXIPAG | Feb 2031 |
| UPTRAVI | SELEXIPAG | Dec 2036 |
| UPTRAVI | SELEXIPAG | Jun 2037 |
| VELETRI | EPOPROSTENOL SODIUM | Feb 2027 |
| VELETRI | EPOPROSTENOL SODIUM | Mar 2027 |
Catalogue
Marketed products
21Showing 21 of 21.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| OPSUMIT | macitentan | TABLET, FILM COATED | NDA |
| OPSYNVI | macitentan and tadalafil | TABLET, FILM COATED | NDA |
| OPSYNVI | macitentan and tadalafil | TABLET, FILM COATED | NDA |
| Tracleer | bosentan | TABLET, FILM COATED | NDA |
| Tracleer | bosentan | TABLET, FILM COATED | NDA |
| Tracleer | bosentan | TABLET, FOR SUSPENSION | NDA |
| UPTRAVI | Selexipag | TABLET, COATED | NDA |
| UPTRAVI | Selexipag | TABLET, COATED | NDA |
| UPTRAVI | Selexipag | TABLET, COATED | NDA |
| UPTRAVI | Selexipag | TABLET, COATED | NDA |
| UPTRAVI | Selexipag | TABLET, COATED | NDA |
| UPTRAVI | Selexipag | TABLET, COATED | NDA |
| UPTRAVI | Selexipag | TABLET, COATED | NDA |
| UPTRAVI | Selexipag | TABLET, COATED | NDA |
| UPTRAVI | Selexipag | INJECTION, POWDER, FOR SOLUTION | NDA |
| UPTRAVI | Selexipag | TABLET, FILM COATED | NDA |
| UPTRAVI | Selexipag | TABLET, FILM COATED | NDA |
| UPTRAVI Titration Pack | Selexipag | KIT | NDA |
| Veletri | epoprostenol | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | NDA |
| Veletri | epoprostenol | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | NDA |
| Zavesca | miglustat | CAPSULE | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.